TIDMVAL

ValiRx PLC

20 June 2023

20 June 2023

ValiRx PLC ("ValiRx" or the "Company")

Virtual AGM Access

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces today an update regarding virtual access to the upcoming Annual General Meeting ("AGM").

In addition to welcoming shareholders to attend the AGM in-person at The Walbrook Building, 25 Walbrook, London, EC4N 8AF, a live webcast of the AGM presentation including Q&A will be made available. Commencing at 11:00am (UK time) on 28 June 2023, investors and analysts are invited to join via registration at https://brrmedia.news/VAL_AGM23 .

The recording of the webcast will also be available for playback from the Company's website, www.valirx.com, shortly after the event.

The Directors of the Company take responsibility for this announcement.

*** ENDS ***

For more information, please contact:

 
 ValiRx plc                                  Tel: +44 (0) 2476 796496 
                                              www.valirx.com 
  Dr Suzanne Dilly, CEO                       Suzanne.Dilly@valirx.com 
 V Formation (Public Relations)              +44 (0) 115 787 0206 
                                              www.vformation.biz 
  Lucy Wharton - Senior PR Executive 
  Sue Carr - Director                         lucy@vformation.biz 
                                              sue@vformation.biz 
                                            -------------------------- 
 Cenkos Securities plc (Joint Broker)        Tel: +44 (0) 20 7397 
                                              8900 
  Dale Bellis/Michael Johnson (Sales) 
 
  Callum Davidson/Giles Balleny (Corporate 
  Finance) 
                                            -------------------------- 
 Turner Pope Investments (Joint Broker)      Tel: +44 (0) 20 3657 
  James Pope / Andy Thacker                   0050 
                                            --------------------------

Notes for Editors

About ValiRx

ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAGPURWQUPWGMB

(END) Dow Jones Newswires

June 20, 2023 02:00 ET (06:00 GMT)

Grafico Azioni Valirx (LSE:VAL)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Valirx
Grafico Azioni Valirx (LSE:VAL)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Valirx